Table 1. IC50 values and p53 status of the cell lines used in this study.
Cell line | IC50 cisplatin (μM)a | IC50 combination (μM)b | Enhancement ratioc | P53 statusd |
---|---|---|---|---|
Tera | 0.69±0.11 | 0.07±0.01 | 9.9 | wt/wt |
Tera-CP | 2.14±0.17 | 0.11±0.02 | 19.5 | wt/wt |
833KE | 1.04±0.10 | 0.13±0.03 | 8.0 | wt/wt |
Scha | 2.91±0.84 | 0.28±0.08 | 10.4 | wt/wt |
2102EP | 4.05±0.66 | 0.39±0.21 | 10.4 | wt/wt |
NCCIT | 2.15±0.34 | 2.25±0.59 | 1.0 | mt/− |
The IC50 (drug concentration reducing cell survival by 50%) for cisplatin was calculated from the graphs in Figure 6a and Supplementary Figures 4a and b. The mean IC50±S.D. was determined in three experiments, each performed in quadruplicate.
The IC50 (drug concentration reducing cell survival by 50%) for cisplatin in combination with 1 μM Nutlin-3 was calculated from the graphs in Figure 6a and Supplementary Figures 4a and b. The mean IC50±S.D. was determined in three experiments, each performed in quadruplicate.
Nutlin-3 enhancement ratios were calculated by dividing the IC50 for cisplatin alone by the IC50 for the combination with cisplatin and 1 μM Nutlin-3.